Genprex Decides To Cease Enrollment In The Acclaim-2 Clinical Trial Due To Difficulties In Recruiting Patients, Citing Competition From Numerous Other Trials.; Limiting The Acclaim-1 Trial To A Single Cohort Due To Resource Prioritization, Reducing...

Benzinga · Aug 14 21:46

Genprex Decides To Cease Enrollment In The Acclaim-2 Clinical Trial Due To Difficulties In Recruiting Patients, Citing Competition From Numerous Other Trials.; Limiting The Acclaim-1 Trial To A Single Cohort Due To Resource Prioritization, Reducing The Potential Breadth Of The Study

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Genprex Decides To Cease Enrollment In The Acclaim-2 Clinical Trial Due To Difficulties In Recruiting Patients, Citing Competition From Numerous Other Trials.; Limiting The Acclaim-1 Trial To A Single Cohort Due To Resource Prioritization, Reducing...

Genprex Decides To Cease Enrollment In The Acclaim-2 Clinical Trial Due To Difficulties In Recruiting Patients, Citing Competition From Numerous Other Trials.; Limiting The Acclaim-1 Trial To A Single Cohort Due To Resource Prioritization, Reducing The Potential Breadth Of The Study

Risk Disclaimer